Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

Yosef Yarden, Moshe Elkabets

Research output: Book/ReportBookpeer-review

Abstract

to the currently approved drugs, both tyrosine kinase inhibitors and monoclonal antibodies, that specifically inhibit growth factor receptors playing driver or survival functions in cancer.
Examines specific targets and the cognate drugs.
Evaluates molecular modes of innate and evolving resistance.
Original languageEnglish
PublisherSpringer
Number of pages242
ISBN (Print)9783030098179
StatePublished - 2018

Publication series

NameResistance to Targeted Anti-Cancer Therapeutics
Volume15
ISSN (Print)2196-5501
ISSN (Electronic)2196-551X

Fingerprint

Dive into the research topics of 'Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways'. Together they form a unique fingerprint.

Cite this